Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Pyrotinib Combined With Etoposide in HER2-positive Advanced Breast Cancer

NCT03923179 is registered in ClinicalTrials.gov with Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT03923179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03923179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Pyrotinib Combined With Etoposide in HER2-positive Advanced Breast Cancer
Lead sponsor
Chinese Academy of Medical Sciences
Phase
Phase 2
Overall status
Unknown status
Start date
April 19, 2019
Completion date
December 31, 2021
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer